Moderna, Inc. (VIE:MRNA)

Market Cap	13.96B +10.6%
Revenue (ttm)	1.90B -56.1%
Net Income	-2.66B
EPS	-6.86
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,729
Average Volume	4,599
Open	35.93
Previous Close	37.52
Day's Range	35.75 - 36.90
52-Week Range	19.48 - 46.89
Beta	n/a
RSI	55.82
Earnings Date	Feb 13, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 5,800
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MRNA

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD